Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer

Anatomical Record

Volumn 292, Issue 8, 2009, Pages 1114-1121

  Zhang, Wei ^a   Chu, Yong Quan ^a   Ye, Zai Yuan ^a   Zhao, Zhong Sheng ^b   Tao, Hou Quan ^a  

^a Key Laboratory of Gastroenterology of Zhejiang Province   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

BFGF mRNA; Gastric cancer; HGF mRNA; Invasion metastasis; Prognosis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD34 ANTIGEN; MESSENGER RNA; SCATTER FACTOR;

ANTIGEN DETECTION; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; GASTROINTESTINAL SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH; STOMACH CANCER; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD34; ENDOTHELIAL CELLS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 70349150152     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.20934     Document Type: Article

References (29)

1. Boros P, Miller CM. 1995. Hepatocyte growth factor: a multifunctional cytokine. Lancet 345:293-295.
2. Bremnes RM, Camps C, Sirera R. 2006. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51:143-158.
3. Brychtova S, Bezdekova M, Brychta T, Tichy M. 2008. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Neoplasma 55:273-279.
4. Gan Y, Wientjes MG, Au JL. 2006. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 23:1324-1331.
5. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. 2006. Expression of bFGF/ FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch 448:68-74.
6. Han ZG, Jiang WG, Hiscox S, Hallett MB, Isoai A, Mansel RE. 1996. Inhibition of motility and invasion of human lung cancer cells by invasion inhibiting factor 2. Surg Oncol 5:77-84.
7. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T, Aburatani H. 2002. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62:233-240.
8. Hirtenlehner K, Pec M, Kubista E, Singer CF. 2002. Influences of stroma-derived growth factors on the cytokine expression pattern of human breast cancer cell lines. Arch Gynecol Obstet 266: 108-113.
9. Hu RH, Ho MC, Wu YM, Lee PH. 2007. Peritoneal fluid contains high concentration of hepatocyte growth factor and vascular endothelial growth factor after resection for hepatocellular carcinoma. Hepatogastroenterology 54:862-865.
10. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. 2007. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 248:219-228.
11. Kitajima Y, Ide T, Ohtsuka T, Miyazaki K. 2008. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer. Cancer Sci 99:1341-1347.
12. Korobko IV, Zinov'eva MV, Allakhverdiev AK, Zborovskaia IB, Svwrdlov ED. 2007. [c-Met and HGF expression in non-small-cell lung carcinomas]. Mol Gen Mikrobiol Virusol 2:18-21.
13. Kuhn H, Konrad J, Holtz S, Salameh A, Gessner C, Hammerschmidt S, Wirtz H. 2006. Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. Lung Cancer 54:149-153.
14. Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. 2006. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 66:2673-2682.
15. Lee KH, Choi EY, Kim MK, Hyun MS, Eun JR, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR. 2008. Hepatocyte growth factor promotes cell survival by phosphorylation of BAD in gastric cancer cells. Oncol Res 17:23-32.
16. Li HW, Shan JX. 2005. Effects of hepatocyte growth factor/scatter factor on the invasion of colorectal cancer cells in vitro. World J Gastroenterol 11:3877-3881.
17. Nakamura S, Niwa T. 2005. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol 16:144-150.
18. Qin LX, Tang ZY. 2002. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 8:385-392.
19. Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF, Comoglio PM. 2007. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive-growth. Oncogene 26:1078-1087.
20. Rosen EM, Knesel J, Goldberg ID, Jin L, Bhargava M, Joseph A, Zitnik R, Wines J, Kelley M, Rockwell S. 1994. Scatter factor modulates the metastatic phenotype of the EMT6 mouse mammary tumor. Int J Cancer 57:706-714.
21. Sheen-Chen SM, Liu YW, Eng HL, Chou FF. 2005. Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev 14:715-717.
22. Takahashi H, Numasaki M, Lotze MT, Sasaki H. 2005. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol Lett 98:189-193.
23. Tomita N, Morishita R, Taniyama Y, Koike H, Aoki M, Shimizu H, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T. 2003. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 107:1411-1417.
24. Vesely D, Astl J, Lastuvka P, Matucha P, Sterzl I, Betka J. 2004. Serum levels of IGF-I, HGF, TGFbeta1, bFGF and VEGF in thyroid gland tumors. Physiol Res 53:83-89.
25. Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, Mildner M, Weninger W, Nakamura T, Tschachler E, Binder BR. 1999. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Invest 79: 427-438.
26. Xia B, Yang T, Xian J, Wang J. 2006. [Serum angiogenin concentration in nasopharyngeal carcinoma patients and its clinical significance]. Lin Chuang Er Bi Yan Hou Ke Za Zhi 20:647-648, 651.
27. Yanai R, Yamada N, Inui-M, Nishida T. 2006. Correlation of proliferative and anti-apoptotic effects of HGF, insulin, IGF-1, IGF-2, and EGF in SV40-transformed human corneal epithelial cells. Exp Eye Res 83:76-83.
28. Yang L. 2006. Incidence and mortality of gastric cancer in China. World J Gastroenterol 12:17-20.
29. Zhang QH, Qian K, Li XJ, Pu J, Wu XT. 2007. [Experimental study of the hepatocyte growth factor contributing to lymphangiogenesis and lymphatic metastasis in gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi 10:212-216.